27 results about "Medication abuse" patented technology

The invention relates to the technical field of biochemical engineering, in particular to a medetomidine hapten, a preparation method of the medetomidine hapten, a medetomidine antigen, a preparation method of the medetomidine antigen, a kit and a medetomidine detection method. The medetomidine hapten is selected from a compound shown in the following structural formula: # imgabs0 #, q is any integer between 1 and 5, and R represents amido or carbonyl. The medetomidine hapten can be used for synthesizing a medetomidine antigen, so that the medetomidine hapten can be used for immunizing to generate an antibody, and adverse reaction caused by using medetomidine or hydrochloride thereof is reduced. Meanwhile, the medetomidine can be applied to rapid diagnosis products such as kits, medetomidine can be simply, conveniently and rapidly detected, and then the phenomenon of drug abuse can be effectively reduced.

In one aspect, a sensor for detecting a drug of abuse (DOA) in a sample is disclosed. In some embodiments, the sensor includes a graphene layer, a plurality of binding agents, which bind to the DOA, coupled to said graphene layer to generate a functionalized graphene layer, and a plurality of electrical conductors electrically coupled to said functionalized graphene layer for measuring an electrical property of said functionalized graphene layer. While in some embodiments, such binding agents are monoclonal antibodies, in other embodiments they are polyclonal antibodies.

Described herein are new dual sigma receptor and dopamine transporter small molecule antagonists. As these compounds are antagonists of both sigma receptors and dopamine transporters, these compounds dose-dependently antagonize stimulant self-administration and also diminish the effects of stimulant effects on dopamine level, thus indicating minimal abuse liability.

The disclosure is directed at an abuse-deterrent pharmaceutical composition comprising a coated antagonist particle, and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. Methods for manufacturing such an abuse-deterrent pharmaceutical composition are also provided.

The present disclosure relates to the method of treating neurological disease in a recreational drug user by administering an effective amount of soticlestat or a pharmaceutically acceptable salt thereof, wherein the treatment does not produce the potential of drug abuse.

The present application relates to the field of immunochromatography, in particular to a sample pad treatment method, a detection method and a chromatography test paper for drug abuse detection, and discloses an immunochromatography test paper for drug abuse detection, which is characterized by a sample pad treatment liquid containing Pluronic F-127.

The present invention discloses a detection device, which includes a cup body. A first channel is provided in the cup body. The first channel includes a sample inlet and two sample outlets for sample outflow. Two separated chambers are also provided in the cup body, namely a first chamber and a second chamber. The first chamber is configured to receive and detect the sample flowing out from the sample outlet, and the second chamber is configured to receive the sample flowing out from the sample outlet. The first chamber and the second chamber can be closed and communicated with each other. The device of the present invention can not only instantaneously detect the abused drugs in the sample, but also collect and preserve the sample for secondary confirmation testing in the laboratory and / or for DNA testing to confirm whether there is drug abuse and to confirm the sample provider. The above-mentioned detected samples all come from the same sample, ensuring the accuracy of the results and reducing errors. Using this device for the detection of abused drugs is simple in operation and high in accuracy.

A value-based method of treating musculoskeletal pain is described, which includes care for the exacerbating coexisting physical and behavioral health concerns and the social determinants of health; all without bundling in surgery. In general, the techniques described may relate to a specific combination of treatment methodologies, including pain management, physical therapy, physical fitness and nutrition, weight management, behavioral health, substance abuse treatment, smoking cessation, reliable case management, and prompt referral for acute or severe pathological conditions.

A method of preparing an abuse deterrent pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. This produces an abuse deterrent pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.

Systems, methods, and computer program products are provided for detecting fluid flow through ultrasonic flow sensors and / or identifying medication diversion. An example system includes at least one processor configured to: generate, using at least one machine learning model, based on a time-series generated by an ultrasonic flow sensor, a predicted start time associated with a start of a flow, a predicted time period associated with the flow, and / or a predicted end time associated with an end of the flow; and / or identify, based on the time-series, in a database, at least one stored feature representation associated with at least one medication type.

The invention provides a determination method of 3-hydroxypropyl nortadalafil, which comprises the following steps: weighing a 3-hydroxypropyl nortadalafil sample, adding a methanol solution, dissolving with methanol, fixing the volume, and preparing a standard stock solution; taking a proper amount of standard stock solution, diluting with a methanol-water solution, and preparing a standard working solution; transferring into a centrifugal tube for centrifugal treatment; filtering the supernate through a microfiltration membrane, and taking a subsequent filtrate; taking a proper amount of the standard working solution, injecting the standard working solution into a high performance liquid chromatography-tandem mass spectrometer, and recording a chromatogram and a mass spectrum; and sequentially injecting the series of standard working solutions into a high performance liquid chromatography-tandem mass spectrometer, and drawing a standard curve. According to the present invention, the blank of the ultra-high performance liquid chromatography-tandem mass spectrometry detection method for the 3-hydroxypropyl nortadalafil is filled, the detection basis is provided for ensuring the food safety law enforcement method, the drug abuse risk is avoided, and the food quality is ensured to meet the standard.

Technologies and techniques for processing drug data in a computer network. Data from a prescription drug monitoring program (PDMP) and medical / prescription data is received for a patient. Image data of the one or more patients is also received from an image capturing device. The PDMP data, medical data and image data is processed to predictably determining a potential drug abuse condition in one of the one or more patients, wherein the predictive determination includes detecting one or more facial emotive expressions from the image data. A file including data relating to the drug abuse condition may be generated and transmitted to the computer network.

Compositions and methods are provided to determine occupancy level of opioid receptors in a subject. The disclosed methods may be performed non-invasively in the inner ear of the subject, and may be performed at a point-of-care location to provide guidance to a practitioner on tapering on pharmacotherapy or on a patient's risk of relapse for substance abuse.

A value-based method of treating musculoskeletal pain is described, which includes care for the exacerbating coexisting physical and behavioral health concerns and the social determinants of health; all without bundling in surgery. In general, the techniques described may relate to a specific combination of treatment methodologies, including pain management, physical therapy, physical fitness and nutrition, weight management, behavioral health, substance abuse treatment, smoking cessation, reliable case management, and prompt referral for acute or severe pathological conditions.

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

A precision dispensing device for liquids, including a device for remote control and monitoring. A dispensing device for liquids, more particularly pharmaceutical compositions, is described that allows remote control for all functions associated with dispensing the drug to the patient so as to prevent abuse. The dispensing device includes a contact or contactless reader, a GPS sensor, and a biometric sensor such as a fingerprint and facial recognition sensor. The dispensing device is connected to the Internet.

The present invention relates to an orally disintegrating pharmaceutical tablet comprising between 0.1 and 21% by weight of cariprazine or a pharmaceutically acceptable salt thereof, between 0.1 and 15% by weight of a disintegrating agent, between 0.1 and 5% by weight of colloidal silica, between 0.1 and 10% by weight of a taste masking agent, between 0.1 and 5% by weight of a lubricant, and up to 100% by weight of a diluent, the percentage being expressed relative to the total weight of the pharmaceutical tablet. The present invention relates to a composition for use in the treatment and / or prevention of pathological conditions requiring modulation of dopamine receptors, the composition is selected from the group consisting of psychosis, drug abuse, cognitive impairment associated with schizophrenia, mild to moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorders, paranotic and delusional disorders, dyskinesia, anxiety, sexual dysfunction, sleep disorders, vomiting, or the like. And attacking behaviors and autism.

1. The name of the design product: drug screening reagent card. 2. The use of the design product: used for qualitative detection of specific drug components in human urine samples to screen for drug abuse. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: combination state diagram. 5. The design for which protection is sought contains color.

The present invention relates to compounds having pharmacological activity against the sigma (σ) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, to methods of preparing such compounds, to pharmacological compositions comprising them and to their use in therapy, in particular against drug abuse and addiction.

The application relates to a computing device for identifying pharmacological phenotypes. Pharmacological phenotypes are predicted for patients who exhibit or are likely to exhibit a primary disease or complication. A machine learning engine may generate statistical models based on training data from a trained patient to predict pharmacological phenotypes, including drug responses and doses, drug adverse events, risk of diseases and complications, drug-gene interactions, drug-drug interactions, and multi-pharmacy interactions. The model can then predict the pharmacological phenotype of a new patient and can make decisions in clinical and research contexts, including drug selection and dosage, changes in drug treatment regimens, multi-pharmacy optimization, monitoring, and the like, to benefit from additional predictive capabilities, as well as to improve the ability to predict the pharmacological phenotype of the new patient. Therefore, adverse events and drug abuse are avoided, drug response is improved, patient recovery results are improved, treatment cost is reduced, public health benefits are improved, and research efficiency in pharmacology and other biomedical fields is improved.

Provided herein are pharmaceutical compositions comprising a denatonium salt and a pharmaceutical agent. Also provided herein are methods for reducing a risk of drug abuse comprising use of a denatonium salt to decrease the likelihood of improper ingestion of a pharmaceutical agent. Also provided herein are methods for making the test of a drug less palatable comprising a subclinical dose of a denatonium salt.

To provide a diversion detection system, a method, a device, and a storage medium for preventing diversion of a medicine.SOLUTION: A method for generating evidence of a diversion event includes detection of a trigger event in a medicine preparation cabinet including a medicine (702). The method includes activation of one or multiple monitoring devices so as to acquire a record according to detection of a trigger event (704). The record includes an event that is suspected of diversion. The method includes generation of one or multiple transaction records related to the record (706). The method includes filtering of multiple records on the basis of one or multiple transaction records in a database (712). The multiple records include a record for specifying whether an event suspected of diversion occurs. According to specification (714) of occurrence of an event suspected of diversion, the method includes generation of an alert showing occurrence of the event suspected of diversion (716).SELECTED DRAWING: Figure 7

The invention is based on a platform for vaccination and / or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.

The disclosure is directed at an abuse-deterrent pharmaceutical composition comprising a coated antagonist particle, and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. Methods for manufacturing such an abuse-deterrent pharmaceutical composition are also provided.

This invention relates to the pharmaceutical field, and particularly to the use of substances that specifically bind to S-100B protein in the preparation of diagnostic or prognostic products for acute retinal necrosis (ARN). By detecting the level of S-100B protein in the aqueous humor, the extent of optic nerve damage caused by ARN can be objectively and accurately observed. This can aid in the early clinical diagnosis of ARN, enabling timely and appropriate treatment, effectively reducing the risk of retinal detachment and blindness, and helping clinicians predict disease progression and visual prognosis, achieving early intervention, precision treatment, and reducing drug abuse and waste of medical resources.

The invention relates to the field of drug monitoring, in particular to a drug abuse monitoring method. A drug abuse monitoring method comprises the following steps: step 1, after a doctor makes a pre-generated prescription through a client, the client uploads the pre-generated prescription to a normal state management server; 2, the normal state management server judges whether the pre-generated prescription relates to the monitored specific medicine or not; if not, converting the pre-generated prescription into a formal prescription, and issuing the formal prescription to the client; if yes, transmitting the pre-generated prescription to a drug abuse monitoring server; and step 3, after the drug abuse monitoring server receives the pre-generated prescription, judging whether abuse exists in each monitored specific drug in the pre-generated prescription in the current drug dosage in the pre-generated prescription or not. The medicine abuse detection device has the advantages that medicine abuse is found in time, the omission risk is avoided, and meanwhile abuse can be prevented before the medicine is used.

For patients who exhibit or are likely to exhibit a primary disease or complication, pharmacologic phenotypes can be predicted by collecting omics, physiomics, environmental, socialomics, demographic, and outcome phenotype data over a period of time. A machine learning engine can generate a statistical model based on training data from training patients to predict pharmacologic phenotypes, which include drug response and dose, drug adverse events, risks of disease and complications, drug-gene interactions, drug-drug interactions, and polypharmacy interactions. The model can then be applied to data from new patients to predict the pharmacologic phenotypes of the new patients and enable decision-making in clinical and research contexts, including drug selection and dosing, changes in drug treatment regimens, polypharmacy optimization, monitoring, etc., to benefit from additional predictive capabilities, thereby avoiding adverse events and drug misuse, improving drug response, improving patient recovery outcomes, reducing treatment costs, enhancing public health benefits, and increasing research efficiency in pharmacology and other biomedical fields.